US Drug Recall Register
Class II · Moderate risk Terminated Initiated Jun 11, 2018 (8 years ago)

Monsel's Solution

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Products not manufactured under current good manufacturing practices.

What was recalled

Monsel's Solution (Ferric Subsulfate), 20%, packaged as 12 single application vials and 12 applicators, 8 mL per box, Manufactured For: MedGyn Products, Inc., 100 W. Industrial Rd., Addison, IL 60101 USA; Manufactured By: BioDiagnostics Intl, 555 West Lambert Road Unit-C, Brea, CA 92821, NDC 42721-112-08.

Recalling firm
BioDiagnostic International
NDC code
42721-112-08
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0874-2018

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Ferric recalls

See all
Class III · Low risk Ongoing

Premier

Reason Labeling: Incorrect or Missing Lot and/or Exp Date:The expiration date has an extra digit and is printed as 2709114 instead of the correct 270914 (2027-09-14). It is important to note that this error is limited to the vial itself; the saleable unit of the box of 12 bottles has the correct expiration date printed.

Premier Dental Products Co NDC 48783-112-08 D-0490-2026
Class II · Moderate risk Completed

AstrinGyn

Reason CGMP Deviations: Products not manufactured under current good manufacturing practices.

Ecometics, Inc. NDC 59365-6065-0 D-1101-2023
Class II · Moderate risk Terminated

Auryxia

Reason CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Cardinal Health Inc. NDC 59922-631-01 D-0499-2021
Class III · Low risk Terminated

Auryxia

Reason Failed Dissolution Specifications

Akebia Therapeutics dba Keryx Biopharmaceutials, Inc NDC 59922-0631-01 D-0260-2021
Class II · Moderate risk Terminated

Auryxia

Reason CGMP Deviations

Akebia Therapeutics dba Keryx Biopharmaceutials, Inc NDC 59922-631-01 D-0170-2021